In HNSCC patients with overexpression of EGFR and cyclin D1, the combined effect of afatinib and palbociclib induces ageing by reducing the ATP pool, reducing antioxidant enzymes, and increasing the production of ROS, thus causing metabolic changes and enhancing the combined antitumour effect [149]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.